OR WAIT null SECS
January 03, 2023
Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?
January 02, 2023
In light of increasingly stringent sustainability requirements, bio/pharma companies need to make sure they formulate effective ESG strategies.
TreeFrog Therapeutics is leaping ahead in cell therapies through resources such as new technologies and investor partnerships.
The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.
Does the new regulatory framework have the potential to incentivise R&D investment in rare diseases?
December 02, 2022
Pharmaceutical Technology Europe got the scoop on Agilent's new Dissolution Testing Centre of Excellence in Craven Arms, UK.
The European Human Medicines Directive and Regulation is due to be updated by the end of 2022, but what changes are on the cards?
Anti-obesity drugs have the potential to be the next blockbusters, according to market analysis.
November 30, 2022
Aptamer’s new 18,000 ft² facility will expand the company's capacity to deliver novel binders for bioprocessing, diagnostic, and drug development.
November 28, 2022
The agreement aims to develop integrated technology for large-scale exosome production.